OVERSEA CHINESE BANKING Corp Ltd Invests $969,000 in Merck & Co., Inc. $MRK

OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the second quarter, Holdings Channel reports. The institutional investor purchased 7,538 shares of the company’s stock, valued at approximately $969,000.

Several other hedge funds also recently modified their holdings of MRK. Norges Bank acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $3,997,933,000. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $1,012,530,000. Jennison Associates LLC acquired a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Merck & Co., Inc. by 37.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last 90 days. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MRK shares. Barclays boosted their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a research report on Wednesday, August 12th. Guggenheim upped their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada cut Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $142.00 to $150.00 in a research note on Thursday, August 20th. Finally, UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $147.60.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $153.21 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $378.00 billion, a P/E ratio of 122.57, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The firm’s fifty day simple moving average is $130.39 and its two-hundred day simple moving average is $122.04. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.